1. ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects
- Author
-
Elena Marcello, Francisco Assis Carvalho Vale, Patricia Regina Manzine, Patricia de Godoy Bueno, Willem Kamphuis, Márcia Regina Cominetti, Sofia Cristina Iost Pavarini, Elly M. Hol, Barbara Borroni, Alessandro Padovani, Carla Manuela Crispim Nascimento, Monica Di Luca, and Netherlands Institute for Neuroscience (NIN)
- Subjects
Blood Platelets ,Male ,Aging ,ADAM10 ,Health, Toxicology and Mutagenesis ,Clinical Biochemistry ,Gene Expression ,Disease ,Neuropsychological Tests ,Biology ,Biochemistry ,ADAM10 Protein ,Downregulation and upregulation ,Alzheimer Disease ,blood ,Gene expression ,Humans ,Toxicology and Mutagenesis ,Cognitive Dysfunction ,Platelet ,RNA, Messenger ,Cognitive impairment ,Aged ,Aged, 80 and over ,Messenger RNA ,Membrane Proteins ,biomarkers ,Middle Aged ,ADAM Proteins ,Health ,Case-Control Studies ,Potential biomarkers ,Immunology ,platelets ,Female ,Amyloid Precursor Protein Secretases ,Biomarkers - Abstract
ADAM10 is a potential biomarker for Alzheimer's disease (AD). ADAM10 protein levels are reduced in platelets of AD patients. The aim was to verify the total blood and platelet ADAM10 gene expression in AD patients and to compare with mild cognitive impairment (MCI) and healthy subjects. No significant differences in ADAM10 gene expression were observed. Therefore, the decrease of ADAM10 protein in platelets of AD patients is not caused by a reduction in ADAM10 mRNA. Further studies must be performed to investigate other pathways in the down regulation of ADAM10 protein.
- Published
- 2015
- Full Text
- View/download PDF